Pharmesis International Ltd
SGX:BFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tele2 AB
STO:TEL2 B
|
SE |
Pharmesis International Ltd
Other Current Liabilities
Pharmesis International Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmesis International Ltd
SGX:BFK
|
Other Current Liabilities
¥136k
|
CAGR 3-Years
-9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥4B
|
CAGR 3-Years
106%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥3.9B
|
CAGR 3-Years
126%
|
CAGR 5-Years
12%
|
CAGR 10-Years
24%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
10%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Other Current Liabilities
¥919.3m
|
CAGR 3-Years
52%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥435.5m
|
CAGR 3-Years
74%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
See Also
What is Pharmesis International Ltd's Other Current Liabilities?
Other Current Liabilities
136k
CNY
Based on the financial report for Dec 31, 2025, Pharmesis International Ltd's Other Current Liabilities amounts to 136k CNY.
What is Pharmesis International Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
63%
Over the last year, the Other Current Liabilities growth was -4%. The average annual Other Current Liabilities growth rates for Pharmesis International Ltd have been -9% over the past three years , 63% over the past five years .
